DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
NEW YORK, March 13, 2018 --
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conference:
- Oppenheimer 28th Annual Healthcare Conference on March 19, 2018 at 10:20 a.m. Eastern Time
Webcast information for this event will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
CONTACT: For more information about
Intercept Pharmaceuticals, please contact:
Intercept Pharmaceuticals:
Mark Vignola
+1-646-747-1000
[email protected]
Media inquiries: [email protected]
Investor inquiries: [email protected]
